RxDoctor Payments Data

Travis Whitt, OD

Optometrist · Bozeman, MTNPI 1720235955

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,918 of the $2,246 with a category attached, or 85.4%. 13 manufacturers reported payments, led by Alcon at 38.9% of the total. Among optometrist clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,246in general payments, 2019–2025

Across 54 payments — averaging $41.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$873
  • Mallinckrodt Hospital Products Inc.$477
  • AbbVie$248
  • Sight Sciences, Inc.$220
  • Dompe US, Inc.$113
  • Biotissue Holdings Inc.$81
  • plus $233 from 7 others
$222,239in research payments, 2019–2025

Across 34 payments — averaging $6536.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$222K

What the payments were for

  • Food & beverage$1,91885%
  • Education$32815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,246 in reported general payments places this provider in the 95th percentile of 184 optometrist providers in Montana.

See all optometrist providers in Montana

Medicare billing

Part B allowed, 2024
$106,066
Medicare patients
499
Services billed
1,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj15$534,687
Prednisolone Acetate54$2,520
Latanoprost111$1,388
ValacyclovirValacyclovir Hcl22$900
MoxifloxacinMoxifloxacin Hcl16$381
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$235
Timolol Maleate24$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$113$534,68715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 184 optometrist providers in Montana.

Other optometrist in Bozeman

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →